Search Results
Jun 13, 2026, 06:33 ET New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
patients with step-up dose 3 in the biweekly dosing schedule (N=153). CRS occurred in 30% of patients with the first 0.4 mg/kg treatment dose and in 12% of patients treated with the first 0.8 mg/kg treatment dose. The CRS rate for both dosing schedules combined was less than 3% for each of the remaining doses
More news about: Johnson & Johnson
Jun 12, 2026, 09:41 ET Bucked Up® Turns 10 With Its Biggest Summer Sale to Celebrate
way."What Else Is NewBucked Up® has been busy. The brand has launched several new products this summer. PWR Buck, a lip pouch delivering 50mg of caffeine and Cognizin® for energy and focus, is available now in Spearmint, Blue Razz, Rocket Pop, and Watermelon. Protein Popcorn, which launched
More news about: Bucked Up
Jun 12, 2026, 09:00 ET Promising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced Ototoxicity
including drug-induced ototoxicity. The exploratory, placebo-controlled, split-body Phase 2a PROHEAR Study assessed the otoprotective efficacy of a 6 mg transtympanic dose of ACOU085 compared to placebo in testicular cancer patients at risk of cisplatin-induced sensorineural hearing loss.Among
More news about: Acousia Therapeutics GmbH
Jun 12, 2026, 09:00 ET Braeburn to Present Research at CPDD 2026 Annual Meeting, Including Data on Withdrawal Suppression and Real-World Treatment Retention in Patients With Opioid Use Disorder
program and comply with the REMS requirements.BRIXADI (buprenorphine) extended-release injection (weekly, 50 mg/mL buprenorphine) and BRIXADI (monthly, 356 mg/mL buprenorphine) are different formulations. Doses of BRIXADI (weekly) cannot be combined to yield an equivalent monthly dose.CONTRAINDICATIONSBRIXADI
More news about: Braeburn
Jun 12, 2026, 08:00 ET Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.
receive bofanglutide injection 24 mg, 36 mg, or 48 mg Q2W or placebo, or 15 mg of tirzepatide injection once weekly for 36 weeks (including a dose-escalation phase).After 36 weeks of treatment, among participants with overweight/obesity without type 2 diabetes, the 48 mg bofanglutide injection group
More news about: Gan & Lee Pharmaceuticals
Jun 12, 2026, 08:00 ET Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
clinical trial with three arms: one arm to receive lurbinectedin 3.2 mg/m2 as monotherapy (the approved dose in the U.S.), the second arm to receive lurbinectedin 2.0 mg/m2 in combination with irinotecan 75 mg/m2, and the third arm to receive topotecan or irinotecan based on
More news about: Jazz Pharmaceuticals plc
Jun 12, 2026, 06:02 ET 12 Press Releases You Need to See This Week
sleep apnea, demonstrating its remarkable potential to treat obesity and its complicationsIn TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesity.
More news about: PR Newswire
Jun 12, 2026, 04:00 ET Promising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced Ototoxicity
including drug-induced ototoxicity. The exploratory, placebo-controlled, split-body Phase 2a PROHEAR Study assessed the otoprotective efficacy of a 6 mg transtympanic dose of ACOU085 compared to placebo in testicular cancer patients at risk of cisplatin-induced sensorineural hearing loss.Among
More news about: Acousia Therapeutics GmbH
Jun 12, 2026, 03:00 ET AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
first dose of VENCLYXTO and at each dose increase. During post marketing surveillance, TLS, including fatal events, has been reported after a single 20 mg dose of venetoclax. The risk of TLS is a continuum based on multiple factors, including comorbidities (particularly reduced renal function), tumour burden,
More news about: AbbVie
Jun 12, 2026, 03:00 ET AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
first dose of VENCLYXTO and at each dose increase. During post marketing surveillance, TLS, including fatal events, has been reported after a single 20 mg dose of venetoclax. The risk of TLS is a continuum based on multiple factors, including comorbidities (particularly reduced renal function), tumour burden,
More news about: AbbVie
Jun 11, 2026, 15:05 ET ERAS INVESTOR ALERT: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead the Erasca Class Action Lawsuit
after market close on April 27, 2026, Erasca reported preliminary Phase I clinical data for ERAS-0015 and disclosed that one patient who received 24 mg of ERAS-0015 had died approximately one month after starting ERAS-0015. Erasca allegedly further disclosed that comparisons between ERAS-0015
More news about: Robbins Geller Rudman & Dowd LLP
Jun 11, 2026, 09:20 ET Herbs, Etc. Wins 2026 Mindful Award for Superfood Product of the Year
convenient, sugar-free powder designed to fit modern, on-the-go lifestyles. The new ChlorOxygen® Lemonade Powder format delivers:50mg of chlorophyll3 grams of dietary fiber per servingNo sugar100% vegan ingredientsSingle-serve stick packs for portabilityIt
More news about: Herbs, Etc.
Jun 11, 2026, 09:00 ET Abbott recebe aprovação para dois novos biossimilares no Brasil, ampliando o acesso ao tratamento da osteoporose e de complicações ósseas relacionadas ao câncer
aprovação regulatória da Anvisa (Agência Nacional de Vigilância Sanitária) para dois novos medicamentos biossimilares de denosumabe no Brasil (60 mg e 120 mg), representando mais um passo significativo para ampliar o acesso a terapias avançadas para osteoporose e complicações ósseas relacionadas ao câncer.
More news about: Abbott
Jun 11, 2026, 09:00 ET WeNatal Launches Iron+ for Targeted Iron Support Across Changing Nutritional Needs
formulated with these common challenges in mind.Each capsule contains 18 mg of Ferrochel® iron bisglycinate, a chelated form selected for its digestive tolerability and supported by clinical research, paired with 100 mg of Pureway-C® liposomal vitamin C to support iron absorption. The formula contains
More news about: WeNatal
Jun 11, 2026, 08:00 ET Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
dose of 80 mg QD (n=62), Grade ≥3 TEAEs were reported in 15/62 (24%) patients, with thrombocytopenia (6%) being the only Grade ≥3 TEAE reported in >5% of patients.Key Outcomes from the End-of-Phase 1 Meeting with the FDA80 mg QD selected
More news about: Enliven Therapeutics, Inc.
Jun 11, 2026, 08:00 ET Setria® Glutathione Earns First Registered Finished Product in Chile Through SEREMI de Salud
The Nutrapharm product contains 500mg of Setria® GlutathioneSetria, a patented, fermentation-derived form of reduced L-glutathione, is established in finished supplement products across
More news about: Kyowa Hakko U.S.A
Jun 11, 2026, 03:05 ET ZINZINO AB (PUBL.): Zinzino launches Collagen Boozt Flex as beauty-from-within enters daily routines
collagen peptides sourced from wild-caught Arctic fish from Norwegian waters, giving the formula a clear Nordic provenance. It also contains 120 mg of hyaluronic acid, vitamin C from acerola cherry, biotin, zinc, rice bran ceramides and the amino acids L-arginine and glycine.A distinguishing
More news about: Zinzino
Jun 11, 2026, 02:20 ET CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
Chemotherapy, ADCs, or Bispecifics)Overall ORR in the 30 mg/kg cohort: 24% (squamous 25%, non-squamous 23.1%, consistent benefit); DCR 60%;In second-line NSCLC (30 mg/kg, post IO + chemotherapy): ORR improved to 30.8%, DCR 84.6%.In such post-PD-(L)1
More news about: CStone Pharmaceuticals
Jun 11, 2026, 02:03 ET IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
IMAAVY and discuss any questions you have with your doctor.Dosage Form and Strengths: IMAAVY is supplied as a 300 mg/1.62 mL and a 1,200 mg/6.5 mL (185 mg/mL) single-dose vial per carton for intravenous injection.ABOUT JOHNSON & JOHNSONAt Johnson & Johnson,
More news about: Johnson & Johnson
Jun 10, 2026, 22:56 ET Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease
proof-of-concept study (NCT06745583) is an ongoing, open-label trial in participants with mild-to-severe Alzheimer's disease. Participants receive enrupatinib 448.2 mg orally twice daily for 28 days, with TSPO-PET as the primary pharmacodynamic endpoint and cognitive and functional assessments as exploratory endpoints.
More news about: Elixiron Immunotherapeutics
Jun 10, 2026, 15:18 ET CDA designates 8 winning projects in its 19th annual North American Copper in Architecture Awards
Fraser Hall Chemistry Undergraduate Teaching Lab (Minneapolis, MN) | Owner: University of Minnesota (Minneapolis, Minnesota) | Sheet Metal Contractor: MG McGrath, Inc. (Maplewood, MN) | Lead Design Architect: VJAA Architects (Minneapolis, MN) | Executive Architect: BWBR Architects, Inc. (St. Paul, MN)
More news about: Copper Development Association
Jun 10, 2026, 14:24 ET Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from Health Canada and import authorization from the UK Home Office
More news about: Optimi Health Corp
Jun 10, 2026, 10:00 ET Hall des Lumières Unveils Renaissance: Da Vinci, Raphael, Michelangelo, A Spectacular Immersive Journey Through The Italian Renaissance
https://renaissance.halldeslumieres.com/?utm_source=google&utm_medium=sc_brand&utm_campaign=634631_nyc&utm_content=810565571423&utm_term=hall%20des%20lumieres%20renaissance_p&gad_source=1&gad_campaignid=23880209001&gbraid=0AAAAADGO9U9L_weyFytDPu3mG3D4kuML3&gcl
More news about: Hall des Lumières
Jun 10, 2026, 09:30 ET Zepbound® (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection.Learn moreZepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979)
More news about: Eli Lilly and Company
Jun 10, 2026, 09:19 ET 퓨처수티컬즈 Caffinity™, 에너지와 운동 능력, 대사 기능에 임상적으로 유의미한 효과 입증
이중맹검, 위약 대조 방식으로 진행된 이번 연구에서 Caffinity 286mg(카페인 200mg 및 커피 과실 유래 폴리페놀 함유)을 섭취한 훈련된 사이클 선수들은 위약군 대비 시간기록 경기(time trial) 수행능력이 유의하게 향상됐으며, 총 운동 수행량이 평균 약 5% 증가한 것으로 나타났다(P < 0.05). 참가자들은 또한 최대 이하의 일정 강도
More news about: FutureCeuticals, Inc.